41 results match your criteria OncoTargets and Therapy [Journal]

  • Page 1 of 1

Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy.

Med Res Rev 2018 Nov 11. Epub 2018 Nov 11.

Centre for Biosystems and Genome Network Medicine, Ioannina University, Ioannina, Greece.

Despite remarkable progress in medium-term overall survival benefit in the adjuvant, neoadjuvant and metastatic settings, with multiple recent targeted drug approvals, acquired resistance, late relapse, and cancer-related death rates remain challenging. Integrated technological systems have been developed to overcome these unmet needs. The characterization of structural and functional noncoding genome elements through next-generation sequencing (NGS) systems, Hi-C and CRISPR/Cas9, as well as computational models, allows for whole genome and transcriptome analysis. Read More

View Article
November 2018

Breakthrough cancer genome analysis in time and space: novel oncotargets and early drug development.

Pharmacogenomics 2018 Nov 23;19(17):1303-1310. Epub 2018 Oct 23.

Centre for Biosystems & Genome Network Medicine, Ioannina University, Ioannina, Greece.

View Article
November 2018

[Retracted] Long non‑coding RNA MALAT1 interacts with miR‑124 and modulates tongue cancer growth by targeting JAG1.

Oncol Rep 2018 Nov 6;40(5):3112. Epub 2018 Sep 6.

Department of Oral and Maxillofacial Surgery, Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong 510055, P.R. China.

We wish to retract our research article entitled "Long non‑coding RNA MALAT1 interacts with miR‑124 and modulates tongue cancer growth by targeting JAG1" published in Oncology Reports 37 2087‑2094, 2017. Following the publication of this article, it was drawn to our attention that this paper bore numerous similarites with an article published previously in the journal OncoTargets and Therapy. Although all the data reported in our study were original, we recognize that it was not appropriate that we should have modelled our paper on previously published articles as a template on which to base the writing of our paper. Read More

View Article
November 2018

Protein-Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway.

Trends Cancer 2018 Sep 9;4(9):616-633. Epub 2018 Aug 9.

Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC) - Universidad de Cantabria, Santander 39011, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid 28029, Spain. Electronic address:

Given the implication of aberrant RAS-extracellular signal-regulated kinase (ERK) signaling in the development of a large number of tumor types, this route is under intense scrutiny to identify new anticancer drugs. Most avenues in that direction have been primarily focused on the inhibition of the catalytic activity of the kinases that participate in this pathway. Although promising, the efficacy of these therapies is short lived due to undesired toxicity and/or drug resistance problems. Read More

View Article
September 2018
1 Read

Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology.

Drug Discov Today 2018 11 2;23(11):1848-1872. Epub 2018 Aug 2.

Centre for Biosystems and Genome Network Medicine, Ioannina University, Ioannina, Greece; Department of Surgery, Ioannina University Hospital, Ioannina, Greece; Department of Systems Biology, Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, Greece. Electronic address:

Despite standardization of multimodal treatment and approval of several targeted drugs for resectable, non-metastatic cancer (M0 patients), intrinsic and acquired resistance and relapse rates remain high, even in early-stage aggressive tumors. Genome analysis could overcome these unmet needs. Our comprehensive review underlines the controversy on stable or spatiotemporally evolving clones as well as promising yet inconclusive data on genome-based biomarkers and drug development. Read More

View Article
November 2018

Neuropeptide G Protein-Coupled Receptors as Oncotargets.

Front Endocrinol (Lausanne) 2018 29;9:345. Epub 2018 Jun 29.

Digestive Diseases Branch, National Institute of Diabetes, Digestive, and Kidney Disease (NIDDK), Bethesda, MD, United States.

Neuropeptide G protein-coupled receptors (GPCRs) are overexpressed on numerous cancer cells. In a number of tumors, such as small cell lung cancer (SCLC), bombesin (BB) like peptides and neurotensin (NTS) function as autocrine growth factors whereby they are secreted from tumor cells, bind to cell surface receptors and stimulate growth. BB-drug conjugates and BB receptor antagonists inhibit the growth of a number of cancers. Read More

View Article
June 2018
2 Reads

An integrated approach identifies new oncotargets in melanoma.

Oncotarget 2018 Feb 15;9(14):11489-11502. Epub 2017 Dec 15.

Department of Medicine, Internal Medicine, Section D, University of Verona, 37134 Verona, Italy.

Melanoma is an aggressive skin cancer; an early detection of the primary tumor may improve its prognosis. Despite many genes have been shown to be involved in melanoma, the full framework of melanoma transformation has not been completely explored. The characterization of pathways involved in tumor restraint in models may help to identify oncotarget genes. Read More

View Article
February 2018
26 Reads

Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening.

J Med Chem 2018 Mar 21;61(5):2104-2110. Epub 2018 Feb 21.

Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine , University of Edinburgh , Crewe Road South , Edinburgh EH4 2XR , U.K.

Pyrazolopyrimidines with potent antiproliferative properties were developed by an adaptive strategy that applies ligand-based design and phenotypic screening iteratively and is informed by biochemical assays. To drive development toward specific oncopathways, compounds were tested against cancer cells that overexpress, or not, AXL kinase. Identified phenotypic hits were found to inhibit oncotargets AXL, RET, and FLT3. Read More

View Article
March 2018
28 Reads

Co-targeting of Tiam1/Rac1 and Notch ameliorates chemoresistance against doxorubicin in a biomimetic 3D lymphoma model.

Oncotarget 2018 Jan 8;9(2):2058-2075. Epub 2017 Dec 8.

Department of Anatomy, Pusan National University School of Medicine, Yangsan 50612, Korea.

Lymphoma is a heterogeneous disease with a highly variable clinical course and prognosis. Improving the prognosis for patients with relapsed and treatment-resistant lymphoma remains challenging. Current drug testing models based on 2D cell culture lack natural tissue-like structural organization and result in disappointing clinical outcomes. Read More

View Article
January 2018
2 Reads

Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model.

Cancer Immunol Immunother 2018 Apr 12;67(4):627-638. Epub 2018 Jan 12.

Cancer Sciences Unit and Cancer Research UK and Experimental Cancer Medicine Centre Protein Core Facility, Faculty of Medicine, University of Southampton, Tremona road, Southampton, SO16 6YD, UK.

Vaccination with DNA that encodes cancer antigens is a simple and convenient way to raise immunity against cancer and has already shown promise in the clinical setting. Conventional plasmid DNA is commonly used which together with the encoded antigen also includes bacterial immunostimulatory CpG motifs to target the DNA sensor Toll-like receptor 9. Recently DNA vaccines using doggybone DNA (dbDNA™), have been developed without the use of bacteria. Read More

View Article
April 2018
12 Reads

Eph receptors as oncotargets.

Oncotarget 2017 Oct 19;8(47):81727-81728. Epub 2017 Sep 19.

Sara Charmsaz: Leukaemia Foundation of Queensland Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; Department of Medicine, University of Queensland, Brisbane, QLD, Australia; Department of Surgery, Royal College of Surgeons, Dublin, Ireland.

View Article
October 2017

Glutathione peroxidases as oncotargets.

Oncotarget 2017 Oct 16;8(45):80093-80102. Epub 2017 Aug 16.

RCMI Cancer Research Center and Department of Chemistry, Xavier University of Louisiana, New Orleans, LA, USA.

Oxidative stress is a disturbance in the equilibrium among free radicals, reactive oxygen species, and endogenous antioxidant defense mechanisms. Oxidative stress is a result of imbalance between the production of reactive oxygen and the biological system's ability to detoxify the reactive intermediates or to repair the resulting damage. Mounting evidence has implicated oxidative stress in various physiological and pathological processes, including DNA damage, proliferation, cell adhesion, and survival of cancer cells. Read More

View Article
October 2017
4 Reads
5 Citations
6.360 Impact Factor

Primary liver cancer genome sequencing: translational implications and challenges.

Expert Rev Gastroenterol Hepatol 2017 Oct 26;11(10):875-883. Epub 2017 Jul 26.

a Centre for Biosystems and Genome Network Medicine , Ioannina University , Ioannina , Greece.

Introduction: The prognosis of primary liver cancer (PLC) remains poor and is explained by the slow progress in understanding the molecular pathways driving tumorigenesis, therapeutic resistance and relapse. For early PLCs, complete surgical resection is the only effective treatment, with sorafenib and, more recently, regorafenib prolonging overall survival by a few months. Areas covered: Application of next-generation sequencing (NGS), including targeted NGS (tNGS), whole-exome sequencing (WES), whole-genome sequencing (WGS) and RNA sequencing (RNAseq), on clinical samples from patients with hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) could aid in comprehending tumorigenesis, genetic and genomic heterogeneity, as well as developing molecular classifications for specialized targeted therapy. Read More

View Article
October 2017
6 Reads

ABCs of RhoGTPases indicating potential role as oncotargets.

J Cancer Res Ther 2017 Jan-Mar;13(1):2-8

Department of Phytochemistry and Pharmacognosy, B. V. Patel Pharmaceutical Education and Research Development (PERD) Centre, Ahmedabad, Gujarat, India.

RhoGTPases also known as molecular switches represent a family of GTP-binding proteins. They shuttle between "On" and "Off" states. In the "On" state, they activate plethora of molecules. Read More

View Article
February 2018
15 Reads

Novel translational therapeutic strategy by sequencing primary liver cancer genomes.

Future Oncol 2017 05 11;13(12):1049-1052. Epub 2017 May 11.

Department of Surgery, Ioannina University Hospital, Ioannina, Greece.

View Article
May 2017
9 Reads

Structural homologies between phenformin, lipitor and gleevec aim the same metabolic oncotarget in leukemia and melanoma.

Oncotarget 2017 Jul;8(30):50187-50192

Department of Pediatrics, University of California Los Angeles School of Medicine, Westwood, CA, USA.

Phenformin's recently demonstrated efficacy in melanoma and Gleevec's demonstrated anti-proliferative action in chronic myeloid leukemia may lie within these drugs' significant pharmacokinetics, pharmacodynamics and structural homologies, which are reviewed herein. Gleevec's success in turning a fatal leukemia into a manageable chronic disease has been trumpeted in medical, economic, political and social circles because it is considered the first successful targeted therapy. Investments have been immense in omics analyses and while in some cases they greatly helped the management of patients, in others targeted therapies failed to achieve clinically stable recurrence-free disease course or to substantially extend survival. Read More

View Article
July 2017
3 Reads

Antitumor effect of combination of the inhibitors of two new oncotargets: proton pumps and reverse transcriptase.

Oncotarget 2017 Jan;8(3):4147-4155

Department of Therapeutic Research and Medicine Evaluation, National Institute of Health, Rome, Italy.

Tumor therapy needs new approaches in order to improve efficacy and reduce toxicity of the current treatments. The acidic microenvironment and the expression of high levels of endogenous non-telomerase reverse transcriptase (RT) are common features of malignant tumor cells. The anti-acidic proton pump inhibitor Lansoprazole (LAN) and the non-nucleoside RT inhibitor Efavirenz (EFV) have shown independent antitumor efficacy. Read More

View Article
January 2017
2 Reads

High Energy Particle Radiation-associated Oncogenic Transformation in Normal Mice: Insight into the Connection between Activation of Oncotargets and Oncogene Addiction.

Sci Rep 2016 11 23;6:37623. Epub 2016 Nov 23.

Department of Pathology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Concerns on high-energy particle radiation-induced tumorigenic transformation of normal tissue in astronauts, and in cancer patients undergoing radiotherapy, emphasizes the significance of elucidating the mechanisms involved in radiogenic transformation processes. Mostly used genetically modified or tumor-prone models are less reliable in determining human health risk in space or protracted post-treatment normal tissue toxicity. Here, in wild type C57BL/6 mice, we related the deregulation of distinctive set of tissue-specific oncotargets in major organs upon Fe (600 MeV/amu; 0. Read More

View Article
November 2016
11 Reads

PRL3-zumab, a first-in-class humanized antibody for cancer therapy.

JCI Insight 2016 06 16;1(9):e87607. Epub 2016 Jun 16.

Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (ASTAR), Singapore.

Novel, tumor-specific drugs are urgently needed for a breakthrough in cancer therapy. Herein, we generated a first-in-class humanized antibody (PRL3-zumab) against PRL-3, an intracellular tumor-associated phosphatase upregulated in multiple human cancers, for unconventional cancer immunotherapies. We focused on gastric cancer (GC), wherein elevated mRNA levels significantly correlated with shortened overall survival of GC patients. Read More

View Article
June 2016
36 Reads

Expression of immune checkpoints in T cells of esophageal cancer patients.

Oncotarget 2016 09;7(39):63669-63678

Cancer Center, Hai'an Hospital Affiliated to Nantong University, Hai'an, China.

Inhibition of immune checkpoint proteins (checkpoints) has become a promising anti-esophageal cancer strategy. We here tested expressions of immune checkpoints in human esophageal cancers. Our results showed the expressions of many immune checkpoints, including CD28, CD27, CD137L, programmed death 1 (PD-1), T cell immunoglobulin mucin-3 (TIM-3), T cell Ig and ITIM domain (TIGIT), CD160, cytotoxic T lymphocyte antigen 4 (CTLA-4), CD200, CD137 and CD158, were dysregulated in peripheral T cells of esophageal cancer patients. Read More

View Article
September 2016
1 Read

Recently discovered EZH2 and EHMT2 (G9a) inhibitors.

Future Med Chem 2016 09 22;8(13):1635-54. Epub 2016 Aug 22.

Department of Pharmacy, 18 Science Drive 4, National University of Singapore, Singapore 117543, Singapore.

Methyltransferase enzymes are promising epigenetic oncotargets. Recent efforts toward the development of inhibitors of two methyltransferases, EZH2 and G9a, as potential anticancer therapies are reviewed with a focus on the structure-activity relationships of compounds published from 2012. Benzamide-substituted 2-pyridones are still by far the most popular selective EZH2 inhibitor class but alternative classes are now being reported. Read More

View Article
September 2016
2 Reads

MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis.

Oncotarget 2016 Jul;7(29):45547-45561

Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA.

Pancreatic cancer is the fourth leading cause of cancer death in the United States. Better understanding of pancreatic cancer biology may help identify new oncotargets towards more effective therapies. This study investigated the mechanistic actions of microRNA-1291 (miR-1291) in the suppression of pancreatic tumorigenesis. Read More

View Article
July 2016
9 Reads

Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults.

Pediatr Blood Cancer 2016 10 15;63(10):1780-5. Epub 2016 Jun 15.

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York.

Background: GD2 and GD3 are the tumor-associated glycolipid antigens found in a broad spectrum of human cancers. GD2-specific antibody is currently a standard of care for high-risk neuroblastoma therapy. In this study, the pattern of GD2 and GD3 expression among pediatric/adolescent or young adult tumors was determined, providing companion diagnostics for targeted therapy. Read More

View Article
October 2016
9 Reads

Pinin interacts with C-terminal binding proteins for RNA alternative splicing and epithelial cell identity of human ovarian cancer cells.

Oncotarget 2016 Mar;7(10):11397-411

Laboratory of Gynecologic Oncology, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, MA, USA.

Unlike many other human solid tumors, ovarian tumors express many epithelial markers at a high level for cell growth and local invasion. The phosphoprotein Pinin plays a key role in epithelial cell identity. We showed that clinical ovarian tumors and ovarian cancer cell lines express a high level of Pinin when compared with normal ovarian tissues and immortalized normal ovarian surface epithelial cell lines. Read More

View Article
March 2016
26 Reads

Viruses, stemness, embryogenesis, and cancer: a miracle leap toward molecular definition of novel oncotargets for therapy-resistant malignant tumors?

Oncoscience 2015 12;2(9):751-4. Epub 2015 Sep 12.

Institute of Engineering in Medicine, University of California, San Diego, La Jolla, CA, USA.

Recent breakthrough studies documented consistent activation of specific endogenous retroviruses in human embryonic stem cells and preimplantation human embryos and demonstrated the essential role of the sustained retroviral activities for maintenance of pluripotency and embryonic stem cell identity. Present analysis has led to the hypothesis that activation of the human stem cell-associated retroviruses (SCARs), namely LTR7/HERVH and LTR5_Hs/HERVK, is likely associated with the emergence of clinically lethal therapy resistant death-from-cancer phenotypes in a sub-set of cancer patients diagnosed with different types of malignant tumors. Read More

View Article
October 2015
1 Read

cnvCurator: an interactive visualization and editing tool for somatic copy number variations.

BMC Bioinformatics 2015 Oct 15;16:331. Epub 2015 Oct 15.

Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA.

Background: One of the most important somatic aberrations, copy number variations (CNVs) in tumor genomes is believed to have a high probability of harboring oncotargets. Detection of somatic CNVs is an essential part of cancer genome sequencing analysis, but the accuracy is usually limited due to various factors. A post-processing procedure including manual review and refinement of CNV segments is often needed in practice to achieve better accuracy. Read More

View Article
October 2015
9 Reads

Estrogenic gper signaling regulates mir144 expression in cancer cells and cancer-associated fibroblasts (cafs).

Oncotarget 2015 Jun;6(18):16573-87

Department of Pharmacy and Health and Nutrition Sciences, University of Calabria, Rende, Italy.

MicroRNAs (miRNAs) are small non coding RNA molecules that play a crucial role in several pathophysiological conditions, including cancer. The stimulation of hormone-sensitive tumors by estrogens are mediated by estrogen receptor (ER)α and G protein estrogen receptor (GPER). Previous studies have reported that ERα regulates miRNA expression, while this ability of GPER remains to be elucidated. Read More

View Article

Deubiquitinating enzymes as oncotargets.

Oncotarget 2015 ;6(12):9657-68

Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle upon Tyne, UK.

Carcinogenesis is a complex process tightly regulated at multiple levels by post-translational modifications. Epigenetics plays a major role in cancer development, all stable changes to the gene expression process that are not a result of a direct change in the DNA code are described as epigenetics. Epigenetic processes are regulated by post-translational modifications including ubiquitination which can directly affect either histones or transcription factors or may target their co-factors and interacting partners exerting an indirect effect. Read More

View Article
April 2016
4 Reads

CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma.

Exp Hematol Oncol 2015 27;4. Epub 2015 Mar 27.

Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA USA.

Background: Comparative genetic and biological studies on malignant tumor counterparts in human beings and laboratory mice may be powerful gene discovery tools for blood cancers, including neoplasms of mature B-lymphocytes and plasma cells such as Burkitt lymphoma (BL) and multiple myeloma (MM).

Methods: We used EMSA to detect constitutive NF-κB/STAT3 activity in BL- and MM-like neoplasms that spontaneously developed in single-transgenic IL6 (interleukin-6) or MYC (c-Myc) mice, or in double-transgenic IL6MYC mice. qPCR measurements and analysis of clinical BL and MM datasets were employed to validate candidate NF-κB/STAT3 target genes. Read More

View Article
April 2015
5 Reads

Oncotargets in different renal cancer subtypes.

Curr Drug Targets 2015 ;16(2):125-35

Institute of Surgical Pathology, University of Zurich, Zurich, Switzerland.

Renal cell cancer is a heterogeneous group of cancers with different histologic subtypes. The majority of renal tumors in adults are clear cell renal cell carcinomas, which are characterized by von Hippel- Lindau (VHL) gene alterations. Recent advances in defining the genetic landscape of renal cancer has shown the genetic heterogeneity of clear cell renal cell carcinomas (ccRCC) and the presence of at least 3 additional ccRCC tumor suppressor genes on chromosome 3p. Read More

View Article
October 2015
2 Reads

Intracellular delivery of peptide cargos using iron oxide based nanoparticles: studies on antitumor efficacy of a BCL-2 converting peptide, NuBCP-9.

Nanoscale 2014 Nov;6(23):14473-83

Center for Biomedical Engineering, Indian Institute of Technology, Delhi,, Hauz Khas, New Delhi-110016, India.

Delivering peptides into cells targeting the undruggable oncoproteins is an emerging area in cancer therapeutics. Here we report a novel nanoparticle-based delivery system that can transport therapeutic cargos to the intracellular sites without the need for a cell transduction or penetration domain (CPP). In the present study, we have used iron oxide nanoparticles to deliver an oncopeptide, NuBCP-9, targeting the BCL-2 BH3 domain. Read More

View Article
November 2014
16 Reads

Dysregulated pH in Tumor Microenvironment Checkmates Cancer Therapy.

Bioimpacts 2013 10;3(4):149-62. Epub 2013 Dec 10.

Research Center for Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.

Introduction: The dysregulation of pH by cancerous cells of solid tumors is able to create a unique milieu that is in favor of progression, invasion and metastasis as well as chemo-/immuno-resistance traits of solid tumors. Bioelements involved in pH dysregulation provide new set of oncotargets, inhibition of which may result in better clinical outcome.

Methods: To study the impacts of pH dysregulation, we investigated the tumor development and progression in relation with Warburg effect, glycolysis and formation of aberrant tumor microenvironment. Read More

View Article
June 2014
7 Reads

GATA2 as a potential metastasis-driving gene in prostate cancer.

Oncotarget 2014 Jan;5(2):451-61

Department of Experimental Therapeutics, BC Cancer Research Centre, Vancouver BC, Canada.

Effective treatment for metastatic prostate cancer is critically needed. The present study was aimed at identifying metastasis-driving genes as potential targets for therapy (oncotargets). A differential gene expression profile of metastatic LTL-313H and non-metastatic LTL-313B prostate cancer tissue xenografts, derived from one patient's specimen, was subjected to integrative analysis using the Ingenuity Upstream Regulator Analysis tool. Read More

View Article
January 2014
12 Reads

Stratifying fascin and cortactin function in invadopodium formation using inhibitory nanobodies and targeted subcellular delocalization.

FASEB J 2014 Apr 10;28(4):1805-18. Epub 2014 Jan 10.

1Department of Biochemistry, Faculty of Medicine and Health Sciences, Ghent University, Albert Baertsoenkaai 3, B-9000 Ghent, Belgium.

Invadopodia are actin-rich protrusions arising through the orchestrated regulation of precursor assembly, stabilization, and maturation, endowing cancer cells with invasive properties. Using nanobodies (antigen-binding domains of Camelid heavy-chain antibodies) as perturbators of intracellular functions and/or protein domains at the level of the endogenous protein, we examined the specific contribution of fascin and cortactin during invadopodium formation in MDA-MB-231 breast and PC-3 prostate cancer cells. A nanobody (K(d)~35 nM, 1:1 stoichiometry) that disrupts fascin F-actin bundling emphasizes the importance of stable actin bundles in invadopodium array organization and turnover, matrix degradation, and cancer cell invasion. Read More

View Article
April 2014
7 Reads

Tapping the treasure of intracellular oncotargets with immunotherapy.

FEBS Lett 2014 Jan 30;588(2):350-5. Epub 2013 Oct 30.

Institute of Molecular and Cell Biology, A(∗)STAR (Agency for Science, Technology and Research), Republic of Singapore; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Republic of Singapore. Electronic address:

It is commonly believed that antibodies are too large (∼150 kDa) to access the intracellular compartment. Therefore, therapeutic antibodies have been traditionally used to target cell surface receptors or soluble proteins in the circulation, leaving a large intracellular treasure of potential cancer-specific targets untapped. This review offers new perspectives on our recently proposed concept that antibodies can be used to target intracellular tumor antigens for anti-cancer therapy. Read More

View Article
January 2014
2 Reads

Glutaminase regulation in cancer cells: a druggable chain of events.

Drug Discov Today 2014 Apr 16;19(4):450-7. Epub 2013 Oct 16.

Department of Molecular Medicine, Cornell University, Ithaca, NY 14853-6401, USA. Electronic address:

Metabolism is the process by which cells convert relatively simple extracellular nutrients into energy and building blocks necessary for their growth and survival. In cancer cells, metabolism is dramatically altered compared with normal cells. These alterations are known as the Warburg effect. Read More

View Article
April 2014
1 Read

The importance of oncogenic transcription factors for oral cancer pathogenesis and treatment.

Oral Surg Oral Med Oral Pathol Oral Radiol 2013 Aug 23;116(2):179-88. Epub 2013 Apr 23.

Centre for Life Sciences, School of Natural Sciences, Central University of Jharkhand, Ranchi, Jharkhand, India.

Oral squamous cell carcinoma is a major cause of morbidity and mortality worldwide. Current experimental evidence shows that most important risk factors for oral cancer include tobacco use and excessive alcohol consumption and less well-defined risks include viral infection and a diet deficient in antioxidants. The positive correlation between various risk/etiologic factors of oral cancer and the activation of various transcription factors (TFs) has been reported in the literature. Read More

View Article

Liposomes and nanotechnology in drug development: focus on oncotargets.

Int J Nanomedicine 2012 14;7:4943-51. Epub 2012 Sep 14.

Department of Biochemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan.

Nanotechnology is the development of an engineered device at the atomic, molecular, and macromolecular level in the nanometer range. Advances in nanotechnology have proven beneficial in therapeutic fields such as drug-delivery and gene/protein delivery. Antigen delivery systems are important for inducing and modifying immune responses. Read More

View Article
January 2013
1 Read

Voltage-dependent K+ channels as oncotargets in malignant gliomas.

Oncotarget 2012 May;3(5):516-7

Because both imipramine and citalopram have been commonly used to treat depression, which commonly occurs in glioma patients, it would be interesting to conduct large epidemiological studies to investigate the actual benefit that these two drugs would provide for malignant glioma patients when delivered during their glioma treatment. Such large-scale epidemiological studies have recently revealed the actual benefit provided by digoxin, a Na+/K+ ATPase inhibitor used to treat heart failure, in prostate cancer patients treated for both prostate cancer and heart failure. Read More

View Article
May 2012
3 Reads

Targeting cancer with peptide aptamers.

Oncotarget 2011 Jul;2(7):557-61

Heat Shock Proteins and Cancer, INSERM, UMR 866 IFR 100, Faculty of Medicine, 7 Boulevard Jeanne D'Arc, 21000 Dijon, France.

A major endeavour in cancer chemotherapy is to develop agents that specifically target a biomolecule of interest. There are two main classes of targeting agents: small molecules and biologics. Among biologics (e. Read More

View Article
July 2011
9 Reads

The pursuit of oncotargets through understanding defective cell regulation.

Oncotarget 2010 Nov;1(7):544-51

Meng Qiao, University of California, Irvine Biological Chemistry, 140 Sprague Hall, 839 Health Sciences Rd, Irvine, CA 92697-1700, USA.

More effective anticancer agents are essential, as has too often been demonstrated by the paucity of therapeutics which preserve life. Their discovery is very difficult. Many approaches are being applied, from testing folk medicines to automated high throughput screening of large chemical libraries. Read More

View Article
November 2010
5 Reads
  • Page 1 of 1